Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 40,004

Document Document Title
WO/2020/190774A1
The present disclosure compounds, as well as their compositions and methods of use. The compounds inhibit the activity of the TEAD transcription factor, and are useful in the treatment of diseases related to the activity of TEAD transcri...  
WO/2020/188571A1
The present invention relates to novel crystalline forms of N-(5,7-dimethoxy- [1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-2-methoxy-4-(trifluoro methyl)pyridine-3-sulfonamide (pyroxsulam) A-G, to processes for their preparation, mixtures and c...  
WO/2020/187865A1
The invention relates to compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.  
WO/2020/190935A1
The present invention discloses compounds of Formula (I), or pharmaceuticall acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical composit...  
WO/2020/189117A1
A π-conjugated compound according to the present invention has a structure represented by general formula (1), while having a HOMO level of -5.3 eV or more. (In the formula, M represents CX1 or a nitrogen atom; each of X1-X6 represents ...  
WO/2020/191261A1
The present invention is directed to indazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.  
WO/2020/186291A1
The present invention provides compounds that modulate biological metals and to pharmaceutical compositions containing such compounds. The invention particularly relates to imidazo[1,5-a]pyridine compounds that modulate iron and are usef...  
WO/2020/187291A1
The present invention relates to the field of biomedicine, and discloses a pyrazolopyrimidine compound, a pharmaceutical composition, and an application therefor, the oxygen-containing substituted pyrazolopyrimidine compound having the s...  
WO/2020/191047A1
Disclosed herein are GABAA receptor modulators and compositions comprising GABAA receptor modulators for treatment of pain and associated conditions such as fibromyalgia. Also disclosed herein are methods of treating pain and associated ...  
WO/2020/191022A1
This disclosure provides methods of treating cancer with an inhibitor of ubiquitin specific peptidase 9X alone or in combination with an immune checkpoint pathway inhibitor.  
WO/2020/185105A1
An improved method for the synthesis of pyrrolo[3,2-b] pyrroles using iron (III) salts as a catalyst is disclosed.  
WO/2020/185755A1
Described herein are compounds that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a ...  
WO/2020/184670A1
The present invention relates to a method for monodeuterated lower alkylating an amine moiety of a compound which contains an amine that is protected by an aralkyl group, wherein a monodeuterated lower alkyl is introduced into the amine ...  
WO/2020/185044A1
The present invention relates to a heteroaryl derivative and a pharmaceutical composition for the prevention or treatment of cancer comprising same as an active ingredient, and a compound according to an aspect of the present invention, ...  
WO/2020/182188A1
Related to the field of pharmaceutics, specifically related to a substituted heteroaryl compound as represented by formula (I), or a stereoisomer, tautomer, nitrogen oxide, solvate, metabolite or pharmaceutically acceptable sale of same,...  
WO/2020/182174A1
The present subject matter relates to fluorescent compounds that have aggregation-induced emission (AIE) characteristics. The compounds exhibit boosted fluorescence, photoacoustic (PA) properties, and Raman properties. The compounds, in ...  
WO/2020/182666A1
The present invention relates to a compound according to formula I and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to, to said compounds for use in therapy, to pharmaceutical compositio...  
WO/2020/185648A1
The present description generally relates to amorphous forms of compounds having enhanced aqueous solubility and dissolution rates and amorphous solid dispersions and oral pharmaceutical formulations thereof, and to processes for prepari...  
WO/2020/186196A1
Compounds having activity as cancer agents are provided. The compounds have the following structure (I) or a pharmaceutically acceptable salts, stereoisomers, tautomers, thereof, wherein R1, R2, R3 and L are as defined herein. This discl...  
WO/2020/182779A1
The invention relates to compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.  
WO/2020/181875A1
Disclosed is a heterocyclic pyrrolo-pyrrole-dione quaternary ammonium salt compound. The structural formula is shown in general formula B: (B) for the definition of each substituent, please refer to the description for details. The heter...  
WO/2020/183295A1
The present invention relates to an improved process for preparation of tofacitinib (I) and pharmaceutically acceptable salt thereof. (I)  
WO/2020/181247A1
The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.  
WO/2020/180907A1
Compounds having the following formula I: or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein all substituents are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα by acting on Tyk-2 to ca...  
WO/2020/180959A1
The present application provides pyrazolyl pyrimidinylamine inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.  
WO/2020/177629A1
Disclosed are a spiro-substituted pyrimidine-fused cyclic compound represented by Formula I or Formula II and pharmaceutically acceptable salts, stereoisomers, solvent compounds or prodrugs thereof. The compound has a selective inhibitor...  
WO/2020/178782A1
The present disclosure relates to compounds of the Formula (I) which have shown utility in modulating AMPA receptor signaling and thus preventing AMPA receptor-mediated toxicity, which may find use in the treatment of diseases in which A...  
WO/2020/180768A1
The present disclosure is directed to modulators of SOS1 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.  
WO/2020/157652A3
This invention relates to compounds of Formula (I), and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R1, R2 and R3 are as defined herein. The invention further relates to phar...  
WO/2020/177657A1
Provided in the present invention is a chemical compound having Btk-degrading activity. Specifically, provided in the present invention is a chemical compound as shown in formula I; definitions of each group are as set forth in the descr...  
WO/2020/181050A1
Disclosed are compounds and compositions for inhibiting the expression of a pattern recognition receptor (e.g., STING), and methods of use thereof.  
WO/2020/177645A1
Disclosed are a new Upadacitinib crystal form and a preparation method therefor, a pharmaceutical composition containing the crystal form, and use of the crystal form in preparation of JAK inhibitors and drugs for treating rheumatoid art...  
WO/2020/178713A1
The present disclosure relates to hydroxypheophorbide compounds with bioactivities towards obesity and obesity-related co-morbidities. Therefore, the present subject-matter discloses hydroxypheophorbide compounds or a pharmaceutically ac...  
WO/2020/180127A1
The present invention relates to a novel compound having excellent electron transport ability and luminescence, and an organic electroluminescent device which comprises same in one or more organic layers and thus has improved characteris...  
WO/2020/178789A1
The present invention discloses a fused heterocyclic compound of general formula (I), Formula (I) wherein, R1, R3, X, A, m and n are as defined in the detailed description. The present invention further discloses methods for their prepar...  
WO/2020/179859A1
The present invention provides a low molecular weight compound or a pharmaceutically acceptable salt thereof that inhibits phosphatidylserine synthase 1, a pharmaceutical containing the same, and a therapeutic for cancer in which the fun...  
WO/2020/178282A1
The specification relates to compounds of Formula (A) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them an...  
WO/2020/176868A1
The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, and methods of improving the bioavailability or other properties of a the...  
WO/2020/176610A1
One aspect described herein includes a method for treating a multiple myeloma (MM) in a subject in need thereof comprising, administering to the subject an effective amount of a small molecule compound. More particularly, another aspect ...  
WO/2020/175309A1
This catalyst for amide compound hydrogenation is capable of carrying out a reduction reaction that converts an amide compound into an amine compound, and is characterized by including rhodium and molybdenum being supported on hydroxyapa...  
WO/2020/175779A1
The present invention provides a novel compound and an organic light emitting device using same.  
WO/2020/173400A1
The present invention relates to a JAK inhibitor compound and the use thereof. Specifically, disclosed in the present invention is a compound as shown in formula (G), or an isotopically labeled compound thereof, or an optical isomer, a g...  
WO/2020/176859A1
The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, and methods of improving the bioavailability or other properties of a the...  
WO/2020/175968A1
The present invention relates to an N-containing heteroaryl derivative and a pharmaceutical composition for the prevention or treatment of cancer, comprising same as an active ingredient, wherein the derivative exhibits high inhibitory a...  
WO/2020/173495A1
The present invention sets forth a salt of an aldose reductase inhibitor shown in formula A-N. The salt being able to be prepared as a crystal form, having notably improved solubility relative to the compound of formula A, having lower h...  
WO/2020/176765A1
The present invention provides novel pyrazolopyridine compounds compounds, compositions and methods for treating or preventing an IRE1α-related disease or disorder. In certain embodiments, the disease or disorder is selected from the gr...  
WO/2020/176755A1
Provided herein are chemically modified luciferase substrates for spectrally shifted emission and enhanced water solubility. Provided herein are engineered luciferases. Moreover, provided herein are new ATP-independent bioluminescent rep...  
WO/2020/173860A1
The invention relates to novel compounds of the formula (I) in which the Q, R1, Ra, Rb, Rc, Rd and n have the meanings given above, to their usee as acaricides and/or insecticides for controlling animal pests and to processes and interme...  
WO/2020/173417A1
The present invention relates to a novel acryloyl-containing compound, a preparation method for same, and uses thereof. Specifically, the present invention relates to an acryloyl-containing compound as represented by formula (1), a prepa...  
WO/2020/173426A1
The present disclosure relates to a compound represented by formula (I) or salts, solvates, isotopically enriched analogs, tautomers, polymorphs, stereoisomers or stereoisomer mixtures thereof, and use thereof in the treatment of tumors....  

Matches 1 - 50 out of 40,004